The effect of combination treatment with trenbolone acetate and estradiol-17β on skeletal muscle expression and plasma concentrations of oxytocin in sheep.

Kongsuwan K, Knox MR, Allingham PG, Pearson R, Dalrymple BP

Domestic animal endocrinology20 Mar 2012Cited by 14 (Europe PMC)

PMID22503145DOI10.1016/j.domaniend.2012.02.004PepBankPUB-22503145

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In wethers, trenbolone acetate plus estradiol-17β treatment increased the body's own oxytocin gene expression in skeletal muscle about 4.4-fold versus untreated wethers.
In plain wordsIn sheep, a growth-implant treatment raised the body's own oxytocin gene activity in muscle, compared with untreated sheep.
Peptide
Oxytocin
Outcome
IncreaseOXT mRNA expression in longissimus muscle
Study
sheep (wethers)n: not reported in source
Comparator
Untreated wethers
Outcome group
Muscle injury and repair · Musculoskeletal
Measurements
OXT mRNA fold change
≈ 4.4 fold
TBA-E2 wethers
Source sentences
Summary
The expression of OXT mRNA in wethers that received the TBA-E(2) treatment was increased ~4.4-fold (P = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to determine whether OXT mRNA expression in the longissimus muscle (LM) is also up-regulated in TBA-E(2-)implanted wethers as has been found in steers.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2250314501
02AnimalEndogenous levelAnimal study (in vivo)Other
In wethers, trenbolone acetate plus estradiol-17β treatment increased circulating oxytocin 2.3-fold versus untreated wethers.
In plain wordsIn sheep, a growth-implant treatment raised the body's own oxytocin level in blood, compared with untreated sheep.
Peptide
Oxytocin
Outcome
IncreaseCirculating OXT
Study
sheep (wethers)n: not reported in source
Comparator
Untreated wethers
Outcome group
Muscle injury and repair · Musculoskeletal
Measurements
Circulating OXT fold change
2.3 fold
TBA-E2 wethers
Source sentences
Summary
TBA-E(2) treatment also induced a 2.3-fold increase in circulating OXT (P = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to determine whether OXT mRNA expression in the longissimus muscle (LM) is also up-regulated in TBA-E(2-)implanted wethers as has been found in steers.
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2250314502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:51 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.